Indeed, ARPCA hampers the capacity of FGF8b to form FGFR1-mediated ternary complexes with HSPGs, thus inhibiting FGFR1 activation and signalling triggered by FGF8b in endothelial and cancer cells. This evidence concerns the gene FGFR1 and cancer.